CYP2C9 is a highly polymorphic gene which may influence metabolism and clearance of ibuprofen, thus affecting drug exposure and potential safety. CYP2C9 isoenzyme is the primary enzyme metabolising (S)-ibuprofen. Ibuprofen is often administered as a racemic mixture of its 2 enantiomers (R)-ibuprofen and (S)-ibuprofen where only the (S)-ibuprofen inhibits the cyclooxygenase enzymes. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines). Use the lowest effective dose for the shortest duration of time.
Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).Ĭhild: >12 years Same as adult dose. In severe or acute cases, may increase to 2,400 mg daily, given in 2 divided doses. As modified-release tab: 1,600 mg once daily (preferably in the early evening). sprains, strains): As conventional tab/cap, effervescent granules: 1,200-1,800 mg daily in divided doses. capsulitis, bursitis, tendinitis, tenosynovitis), and soft-tissue injuries (e.g. rheumatoid arthritis, ankylosing spondylitis, osteoarthritis), peri-articular conditions (e.g. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).Īdult: For short-term symptomatic relief of dysmenorrhoea, dental pain, post-operative pain, headache, low back pain, neuralgia, rheumatic disease (e.g. All doses to be given via IV infusion over 30 minutes. Max: 600 mg 10-11 years weighing 30-39 kg: 200 mg 4 times daily. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).Ĭhild: For short-term symptomatic treatment when administration by IV route is clinically justified or when other routes of administration are not possible: 6-9 years weighing 20-29 kg: 200 mg tid. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).Īdult: For short-term symptomatic treatment when administration by IV route is clinically justified or when other routes of administration are not possible: Initially, 400 mg, may be followed by 400 mg 4-6 hourly or 100-200 mg 4 hourly as necessary via IV infusion over 30 minutes.
Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).Ĭhild: For short-term symptomatic treatment of acute moderate pain, when administration by IV route is clinically justified or when other routes of administration are not possible: 6-9 years weighing 20-29 kg: 200 mg tid. Adult: For short-term symptomatic treatment of acute moderate pain, when administration by IV route is clinically justified or when other routes of administration are not possible: 400-800 mg 6 hourly as necessary via IV infusion over 30 minutes.
0 kommentar(er)
